Menu
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
-
 
WKN: A3D2GA / Symbol: YMTX / Name: Kineta / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Kineta Inc. Stock

Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Kineta Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Kineta Inc. in the next few years

Pros
?
S********** s********
?
M***** P*******
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Prediction Buy
Perf. (%) 25.76%
Target price 6.855
Change
Ends at 15.03.18

(Zielkurs erreicht)
Show more

Prediction Buy
Perf. (%) 25.76%
Target price 6.855
Change
Ends at 15.03.18

Schwer vorherzusagen

Schwer vorherzusagen! Wo sind die Finanzen auf diesem einen ?! Die Grafik ist überall zu sehen.

Show more

News

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at CanaccordPhoto, wide shot, wide-angle lens, soft focus,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

Key Points